Inhibition of erbB-2-positive breast cancer cell growth by erbB-2 antisense oligonucleotides.
Overexpression of erbB-2 proto-oncogene has been found in 20%-30% of human breast carcinomas and in most cases correlates with poor clinical prognosis. Using antisense oligonucleotides targeted to the 5' cap region of erbB-2RNA, we were able to inhibit erbB-2 protein expression, proliferation, and anchorage-independent growth of breast cancer cells up to 90%. These effects were sequence specific and restricted to cells expressing elevated level of erbB-2 protein. These support the feasibility of using antisense erbB-2 oligonucleotides to inhibit the progression of erbB-2-overexpressing breast cancer cells.
Liu
X
X
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
Pogo
B G
BG
D000970:Antineoplastic Agents / Q000737:chemistry / Q000633:toxicity*; D001483:Base Sequence; D014408:Biomarkers, Tumor; D015153:Blotting, Western; D001943:Breast Neoplasms; D002448:Cell Adhesion; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000633:toxicity*; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D012315:RNA Caps; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000096:biosynthesis; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D016376:Oligonucleotides, Antisense; D000090063:Proto-Oncogene Mas; D012315:RNA Caps; D018719:Erb-b2 Receptor Tyrosine Kinases; C000715470:MAS1 protein, human